A phase I clinical trial attempted to deplete MDSCs by administering an antagonistic TNF-related apoptosis induced ligand-receptor 2 (TRAIL-R2) antibody in patients with various metastatic cancers, including pancreatic cancer. Here, TNFRSF10B is linked to familial pancreatic carcinoma.